DAFNA Capital Management LLC Sells 122,840 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR)

DAFNA Capital Management LLC reduced its position in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 24.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 371,434 shares of the company's stock after selling 122,840 shares during the period. DAFNA Capital Management LLC owned approximately 0.58% of Larimar Therapeutics worth $1,437,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in shares of Larimar Therapeutics by 35.1% during the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock worth $75,000 after buying an additional 5,042 shares in the last quarter. Barclays PLC raised its stake in Larimar Therapeutics by 321.2% in the 3rd quarter. Barclays PLC now owns 60,032 shares of the company's stock worth $393,000 after purchasing an additional 45,781 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Larimar Therapeutics by 18.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company's stock valued at $143,000 after purchasing an additional 3,425 shares during the period. Adage Capital Partners GP L.L.C. grew its position in shares of Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company's stock worth $8,127,000 after purchasing an additional 399,123 shares in the last quarter. Finally, Blue Owl Capital Holdings LP increased its holdings in shares of Larimar Therapeutics by 11.7% during the fourth quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company's stock worth $18,007,000 after purchasing an additional 486,211 shares during the period. 91.92% of the stock is currently owned by institutional investors.

Larimar Therapeutics Price Performance

Shares of NASDAQ LRMR traded down $0.12 during mid-day trading on Friday, hitting $2.12. 783,998 shares of the stock traded hands, compared to its average volume of 757,276. The company has a market cap of $135.74 million, a PE ratio of -1.84 and a beta of 0.93. Larimar Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $11.20. The firm has a 50 day simple moving average of $2.30 and a two-hundred day simple moving average of $4.04.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.04). On average, equities research analysts anticipate that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

LRMR has been the topic of a number of recent research reports. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Guggenheim restated a "buy" rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Robert W. Baird cut their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. HC Wainwright raised their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a report on Tuesday, March 25th. Finally, Truist Financial assumed coverage on shares of Larimar Therapeutics in a research report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 target price for the company. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $19.63.

Larimar Therapeutics Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.